154140-57-5Relevant academic research and scientific papers
CYCLIC COMPOUNDS AND METHODS OF USING SAME
-
Page/Page column 296-297, (2021/07/02)
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
Synthesis of 3,3-difluoro-DL-alanine and 3,3-difluoro-DL-alanine precursors
D'Orchymont
, p. 961 - 963 (2007/10/02)
The key intermediate to 3,3-difluoroalanine, 2,2-difluoro-1-ethylthioethylamine hydrobromide (2), was prepared by the Steglich and Weygand procedure. Its conversion to N-benzyloxycarbonyl-2,2-difluoro-1-ethenylethylamine (5) followed by oxidation and subsequent deprotection of the amine afforded the 3,3-difluoroalanine.
